Clinical Trials in Boston

Showing 401-420 of 8,503 trials

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

NCT07070466

This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.

Stomach Cancer Stage IVEsophagus CancerStomach Cancer

Massachusetts General Hospital40 participantsStarted Oct 2025

Santa Monica, California, United States • Boston, Massachusetts, United States

RECRUITINGPHASE1/PHASE2< 1 mile

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161

The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.

Metastatic Prostate Cancer

AstraZeneca177 participantsStarted Oct 2025

Fayetteville, Arkansas, United States • Los Angeles, California, United States • Boston, Massachusetts, United States +48 more locations

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Find Trials by Condition in Boston

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

Medtronic Terminate AF Study

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol

Physical Activity for PLWH and Unhealthy Drinking

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

Trifecta-Lung cfDNA-MMDx Study

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)